



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): **J seph a. Kozl wski t al.** : Group Art Unit: **1625**
Serial No.: **10/072,354** : Examiner: **Coppins, Janet L.**
Filed: **02/06/2002** : Attorney Docket No. : **AL01381K**
For: **Cannabinoid Receptor Ligands** :
X

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) _____ filed _____, respectively.

(b) No fee is believed due because:

- ☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ This Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☒ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) ☐ This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

- (d) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- ☐ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0395, Patent Case No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
SCHERING-PLOUGH CORPORATION

Dated: 09/16/2003
SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

By: _____

Name: **Ann M. Cannoni**
Reg. No.: **35,972**
Attorney of Record
Telephone No.: (908) 298-5024

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

AL01381K

SERIAL NO.:

10/072,354

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

JOSEPH A. KOZLOWSKI et al.

FILING DATE:

02/06/2002

GROUP:

1625

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AB	4466965	08/21/84	Stout et al.			
AC	4567184	01/28/86	Musser et al.			
AD	5332820	07/26/94	Duncia et al.			
AE	5486525	01/23/96	Summers, Jr. et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
AF	DE19533644	09/12/95	GERMANY				
AG	EP0181568	10/30/85	EPO				
AH	EP0401030	05/31/90	EPO				
AI	EP0407217	07/06/90	EPO				
AJ	EP1031571	10/23/98	EPO				
AK	EP1283039	05/18/01	EPO				
AL	WO 93/21158	10/28/93	PCT				
AM	WO 96/23783	08/08/96	PCT				
AN	WO 97/03953	02/06/97	PCT				
AO	WO 98/10763	03/19/98	PCT				
AP	WO 98/31227	07/23/98	PCT				
AQ	WO 98/33769	08/06/98	PCT				
AR	WO 98/41519	09/24/98	PCT				
AS	WO 99/26612	06/06/99	PCT				
AT	WO 99/50245	10/07/99	PCT				
AU	WO 00/06146	02/10/00	PCT				
AV	WO 01/37826	05/31/01	PCT				
AW	WO 01/44172	06/21/01	PCT				
AX	WO 01/44239	06/21/01	PCT				
AY	WO 01/64642	09/07/01	PCT				
AZ	WO 03/042174	05/22/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BA	Chemical Abstract of M. Curtin et al., "Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists", 41(1) J. Med. Chem. 74-95 (1998)
BB	Chemical Abstract of G. Hartman et al., "4-Substituted Thiophene - and Furan - 2-sulfonamides as topical carbonic anhydrase inhibitors" 35(21) J. Med. Chem. 3822-31 (1992)
BC	Chemical Abstract of G. Hartman et al., "Synthesis and derivatization of 4-(arylsulfonyl) thiophene -and - furan - 2 sulfonamides", 27(2) J. Heterocycl. Chem. 127 - 34 (1990)
BD	Chemical Abstract of P. Cozzi et al., "New N-(2-ethoxyethyl)-N-(4-phenoxybenzyl) dichloroacetamides as potent antiamebic agents 18(3) Eur. J. Med. Chem. 203-208 (1983)
BE	Chemical Abstract of WO 200183460 A1
BF	Chemical Abstract of WO 99/36393 A1
BG	Chemical Abstract of JP 06072979 A1
BH	U.S. Patent Application No. 03/024,398 (AL01381K1) for "Cannabinoid Receptor Ligands", filed August 5, 2003
BI	U.S. Patent Application No. 10/464,174 (AL01561K) for "Cannabinoid Receptor Agonists", filed June 17, 2003

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.